| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 48 | 2021 | 1138 | 1.800 |
Why?
|
| Lung Neoplasms | 56 | 2023 | 2394 | 1.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2021 | 2556 | 1.140 |
Why?
|
| Advisory Committees | 1 | 2022 | 91 | 0.780 |
Why?
|
| Medical Oncology | 1 | 2022 | 393 | 0.600 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 3 | 2009 | 13 | 0.600 |
Why?
|
| Vinblastine | 13 | 2002 | 100 | 0.540 |
Why?
|
| Paclitaxel | 15 | 2008 | 495 | 0.510 |
Why?
|
| Ifosfamide | 12 | 2003 | 48 | 0.440 |
Why?
|
| Combined Modality Therapy | 26 | 2010 | 1733 | 0.390 |
Why?
|
| Adenocarcinoma | 12 | 2016 | 1191 | 0.370 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 339 | 0.370 |
Why?
|
| Survival Rate | 22 | 2021 | 1927 | 0.320 |
Why?
|
| Cisplatin | 15 | 2010 | 602 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2019 | 1091 | 0.320 |
Why?
|
| Antineoplastic Agents | 12 | 2019 | 2368 | 0.320 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 13 | 2008 | 167 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2008 | 275 | 0.290 |
Why?
|
| Camptothecin | 4 | 2008 | 198 | 0.270 |
Why?
|
| Neoplasm Staging | 22 | 2019 | 2035 | 0.270 |
Why?
|
| Aged | 53 | 2021 | 19943 | 0.270 |
Why?
|
| Nucleosides | 1 | 2006 | 23 | 0.250 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1576 | 0.250 |
Why?
|
| Middle Aged | 55 | 2021 | 27030 | 0.230 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 136 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 236 | 0.220 |
Why?
|
| Radiosurgery | 2 | 2021 | 297 | 0.220 |
Why?
|
| Humans | 74 | 2023 | 92337 | 0.210 |
Why?
|
| Female | 60 | 2021 | 47893 | 0.190 |
Why?
|
| Male | 58 | 2021 | 43925 | 0.190 |
Why?
|
| Adult | 48 | 2021 | 27532 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 137 | 0.190 |
Why?
|
| Taxoids | 7 | 2012 | 126 | 0.180 |
Why?
|
| Carboplatin | 8 | 2008 | 321 | 0.180 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2008 | 1939 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2019 | 234 | 0.170 |
Why?
|
| Capecitabine | 1 | 2020 | 92 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 1998 | 134 | 0.160 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 3775 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 622 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 22 | 0.160 |
Why?
|
| Precision Medicine | 2 | 2016 | 425 | 0.160 |
Why?
|
| Remission Induction | 10 | 2011 | 763 | 0.150 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 416 | 0.150 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 6916 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2019 | 153 | 0.150 |
Why?
|
| Benzamides | 1 | 2019 | 239 | 0.150 |
Why?
|
| Treatment Outcome | 17 | 2014 | 8740 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 205 | 0.140 |
Why?
|
| Blood Group Incompatibility | 2 | 2009 | 22 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2015 | 88 | 0.140 |
Why?
|
| Piperazines | 1 | 2019 | 288 | 0.140 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 297 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 1398 | 0.130 |
Why?
|
| Pneumonectomy | 4 | 2011 | 215 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 598 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 725 | 0.120 |
Why?
|
| Prognosis | 9 | 2021 | 3872 | 0.120 |
Why?
|
| Interferon-alpha | 4 | 1997 | 214 | 0.120 |
Why?
|
| Carcinoma | 1 | 1998 | 438 | 0.120 |
Why?
|
| Fluorouracil | 9 | 1998 | 549 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3053 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 62 | 0.110 |
Why?
|
| Mesna | 2 | 2008 | 9 | 0.110 |
Why?
|
| Disease Progression | 6 | 2023 | 1503 | 0.110 |
Why?
|
| Drug Administration Schedule | 12 | 2003 | 868 | 0.110 |
Why?
|
| Exanthema | 1 | 2014 | 41 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2014 | 149 | 0.100 |
Why?
|
| Leucovorin | 8 | 1998 | 222 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2012 | 1071 | 0.100 |
Why?
|
| Organoplatinum Compounds | 2 | 2004 | 95 | 0.100 |
Why?
|
| Ketones | 1 | 2012 | 14 | 0.100 |
Why?
|
| Furans | 1 | 2012 | 18 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2016 | 550 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 246 | 0.090 |
Why?
|
| Glutamates | 2 | 2014 | 89 | 0.090 |
Why?
|
| Guanine | 2 | 2014 | 207 | 0.090 |
Why?
|
| United States | 2 | 2022 | 7348 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 174 | 0.090 |
Why?
|
| Recombinant Proteins | 6 | 2008 | 1016 | 0.090 |
Why?
|
| Thigh | 1 | 1990 | 40 | 0.080 |
Why?
|
| ErbB Receptors | 4 | 2015 | 498 | 0.080 |
Why?
|
| Neutropenia | 6 | 2008 | 217 | 0.080 |
Why?
|
| Cladribine | 1 | 2009 | 35 | 0.080 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 16 | 0.080 |
Why?
|
| Splenectomy | 1 | 2009 | 82 | 0.080 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 123 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 66 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 1181 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 79 | 0.080 |
Why?
|
| Transplantation | 1 | 2009 | 37 | 0.080 |
Why?
|
| Vidarabine | 1 | 2009 | 144 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 65 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 109 | 0.070 |
Why?
|
| Rituximab | 1 | 2009 | 123 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 91 | 0.070 |
Why?
|
| Survival Analysis | 7 | 2011 | 1511 | 0.070 |
Why?
|
| Mutation | 5 | 2023 | 4204 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 5 | 2011 | 268 | 0.070 |
Why?
|
| Drug Tolerance | 3 | 1996 | 64 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 214 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 278 | 0.070 |
Why?
|
| Thoracic Neoplasms | 2 | 1998 | 66 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 1015 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 164 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2007 | 337 | 0.060 |
Why?
|
| Histocompatibility | 1 | 2006 | 66 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2006 | 70 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 101 | 0.060 |
Why?
|
| Filgrastim | 3 | 2008 | 58 | 0.060 |
Why?
|
| Radiotherapy Dosage | 4 | 2001 | 475 | 0.060 |
Why?
|
| Gene Amplification | 2 | 2019 | 137 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2008 | 800 | 0.060 |
Why?
|
| Neoplasms | 3 | 1997 | 3117 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2004 | 55 | 0.050 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 800 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 19 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 989 | 0.050 |
Why?
|
| Etoposide | 4 | 2008 | 206 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 209 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 5430 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1399 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 355 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 923 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 61 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 34 | 0.040 |
Why?
|
| Pemetrexed | 2 | 2014 | 76 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2021 | 9703 | 0.040 |
Why?
|
| North America | 1 | 2000 | 188 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1999 | 6 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1999 | 12 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1999 | 36 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 498 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 485 | 0.040 |
Why?
|
| Europe | 1 | 2000 | 328 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1194 | 0.040 |
Why?
|
| Agranulocytosis | 2 | 1995 | 20 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 46 | 0.040 |
Why?
|
| Macrolides | 2 | 2012 | 31 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2011 | 318 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4468 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 810 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2458 | 0.040 |
Why?
|
| Esophagus | 1 | 1998 | 107 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 1995 | 168 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 358 | 0.030 |
Why?
|
| Expectorants | 1 | 1996 | 6 | 0.030 |
Why?
|
| Chicago | 3 | 2014 | 1466 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 98 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1863 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 238 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2011 | 230 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1998 | 445 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 18 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 114 | 0.030 |
Why?
|
| Hydroxyurea | 4 | 1995 | 239 | 0.030 |
Why?
|
| Esophagitis | 3 | 1998 | 43 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 498 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 8 | 0.020 |
Why?
|
| Indoles | 1 | 1994 | 306 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 14 | 0.020 |
Why?
|
| Platinum | 1 | 2012 | 65 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2447 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1744 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 17 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 866 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2003 | 219 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1756 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2001 | 673 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 132 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 806 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 1989 | 6 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1989 | 30 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 200 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1763 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2007 | 2978 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 20 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 289 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 977 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5704 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 358 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 268 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 28 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 133 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1850 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 807 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 361 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 1992 | 304 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Leukemia | 1 | 1987 | 321 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2007 | 324 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 67 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 400 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 26 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 6624 | 0.010 |
Why?
|
| Premedication | 1 | 2003 | 57 | 0.010 |
Why?
|
| Sex Factors | 2 | 2000 | 1095 | 0.010 |
Why?
|
| Smoking | 2 | 2000 | 640 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 272 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 80 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 23 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1337 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1998 | 1150 | 0.010 |
Why?
|
| Methotrexate | 2 | 1992 | 245 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 367 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 296 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 136 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 296 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 69 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 127 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 900 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 62 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2680 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 709 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 88 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 92 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1999 | 122 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 351 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 75 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 310 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1997 | 20 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 23 | 0.010 |
Why?
|
| Leukopenia | 1 | 1997 | 67 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 595 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 128 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 312 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 1277 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1661 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 1905 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 35 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1996 | 158 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1807 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 9 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 263 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 78 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 304 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 183 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 239 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 600 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1994 | 153 | 0.010 |
Why?
|
| Procarbazine | 1 | 1992 | 38 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 175 | 0.010 |
Why?
|
| Vincristine | 1 | 1990 | 109 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 887 | 0.010 |
Why?
|
| Bleomycin | 1 | 1990 | 103 | 0.010 |
Why?
|
| Vindesine | 1 | 1989 | 9 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 359 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1989 | 49 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1989 | 45 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1989 | 68 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 254 | 0.000 |
Why?
|
| Cytarabine | 1 | 1990 | 222 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 217 | 0.000 |
Why?
|
| Thiotepa | 1 | 1989 | 32 | 0.000 |
Why?
|
| Melphalan | 1 | 1989 | 100 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 66 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1990 | 871 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 996 | 0.000 |
Why?
|
| Karyotyping | 1 | 1987 | 252 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1989 | 332 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1989 | 406 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 856 | 0.000 |
Why?
|